Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — FY2023/24 Earnings Presentation
11 slides from Coloplast A/s Class B's earnings presentation, 2024
Slide 1: Conference call presentation FY 2023/24
Conference call presentation FY 2023/24 Making life easier Strive25: Sustainable Growth Leadership Victoria, User, Ostomy Care Ostomy Care | Continence Care | Advanced Wound Care | Interventional Urology | Voice and Respiratory Care
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: FY 2023/24 financial result in line with guidance
NEW IMAGE FY 2023/24 financial result Otto: add picture in line with guidance with Peristeen Light Update picture Organic Reported ROIC growth EBIT margin 8% 27% * * 15% ** Update picture *before special items **after tax and before special items 3 Theresa | Continence Care user
Slide 4: Strategic highlights from Strive25 – Sustainable growth leadership
Strategic highlights from Strive25 – Sustainable growth leadership Growth Innovation Atos Medical Luja , a new intermittent catheter with a Micro-hole Zone Technology • 11% growth in 2023/24 with solid contributions from both Laryngectomy and Tracheostomy. • Launch of Luja for men in key markets con
Slide 5: FY 2023/24 organic growth of 8%, driven by Chronic Care
FY 2023/24 organic growth of 8%, driven by Chronic Care and double- digit growth in Voice & Respiratory Care and Advanced Wound Care FY 2023/24 revenue by business area FY 2023/24 revenue by geography Business Reported revenue Organic growth Share of organic Geographic Reported revenue Organic growt
Slide 6: FY 2023/24 reported revenue grew 10%
FY 2023/24 reported revenue grew 10% with ~4%-points contribution from Kerecis and ~1%-point negative impact from currencies FY 2023/24 Revenue development (mDKK) FY 2023/24 highlights • Reported revenue increased by DKK 2,530 million or 10% vs. last year. +2,530 • Organic growth was 8% or DKK 1,899
Slide 7: FY 2023/24 reported EBIT margin of 27%
FY 2023/24 reported EBIT margin of 27%1, impacted by ~100 basis points dilution from Kerecis, as expected, and currency headwind FY 2023/24 EBIT margin development before special items (%) FY 2023/24 highlights • Gross margin was 68%, against 67% last year • Positive impact from: ~100 bps contributi
Slide 8: 2023/24 adjusted FCF of DKK 3.9 billion
2023/24 adjusted FCF of DKK 3.9 billion. Operating cash flow impacted by the extraordinary tax payment related to the Atos Medical IP transfer FCF development1 FY 2023/24 highlights • Free cash flow for FY 2023/24 was an inflow of DKK 1,430 million, 98 compared to an outflow of DKK 4,731 million las
Slide 9: FY 2024/25 financial guidance
FY 2024/25 financial guidance: organic growth of 8-9% and an EBIT margin before special items of around 28% Organic revenue growth 8-9% Reported revenue growth in DKK 8-9% Reported EBIT margin* Around 28% Effective tax rate Around 22% Capital expenditures Around 1.4 bn DKK *before special items 9
Slide 10: The Coloplast Executive Leadership Team
The Coloplast Executive Leadership Team Kristian Villumsen Anders Lonning-Skovgaard Dorthe Rønnau Allan Rasmussen President, CEO EVP, CFO EVP, People & Culture EVP, Operations With Coloplast since 2008 With Coloplast since 2006 With Coloplast since 2022 With Coloplast since 1992 Nicolai Buhl Anderse
Slide 11: Making life easier for people with intimate healthcare needs
Mission Making life easier for people with intimate healthcare needs Values Closeness… to better understand Passion… to make a difference Respect and responsibility… to guide us Vision Setting the global standard for listening and responding